Zhejiang Huahai Pharmaceutical Co Ltd (600521) — Capital Reinvestment Ratio
Zhejiang Huahai Pharmaceutical Co Ltd (600521) has a Capital Reinvestment Ratio of 1.47x as of September 2025, meaning it reinvests 1% of its operating cash flow (CN¥282.81 Million) in capital expenditures (CN¥414.56 Million). See Zhejiang Huahai Pharmaceutical Co Ltd net asset quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Zhejiang Huahai Pharmaceutical Co Ltd Capital Reinvestment Ratio (2001–2025)
This chart tracks Zhejiang Huahai Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 25 annual periods. Check 600521 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Zhejiang Huahai Pharmaceutical Co Ltd (2001–2025)
Year-by-year Capital Reinvestment Ratio for Zhejiang Huahai Pharmaceutical Co Ltd from 2001 to 2025. For live market cap and broader valuation context, see 600521 company net worth.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 1.60x | CN¥1.23 Billion | CN¥1.97 Billion | ▲ +87.4% |
| 2024 | 0.85x | CN¥2.17 Billion | CN¥1.85 Billion | ▲ +18.8% |
| 2023 | 0.72x | CN¥2.22 Billion | CN¥1.59 Billion | ▼ -61.5% |
| 2022 | 1.86x | CN¥1.24 Billion | CN¥2.32 Billion | ▼ -28.2% |
| 2021 | 2.59x | CN¥938.43 Million | CN¥2.43 Billion | ▲ +216.1% |
| 2020 | 0.82x | CN¥1.56 Billion | CN¥1.28 Billion | ▲ +81.2% |
| 2019 | 0.45x | CN¥1.75 Billion | CN¥794.31 Million | ▼ -97.3% |
| 2018 | 16.56x | CN¥67.90 Million | CN¥1.12 Billion | ▲ +1038.6% |
| 2017 | 1.45x | CN¥546.24 Million | CN¥794.54 Million | ▼ -14.0% |
| 2016 | 1.69x | CN¥433.10 Million | CN¥732.88 Million | ▼ -37.0% |
| 2015 | 2.68x | CN¥195.31 Million | CN¥524.28 Million | ▲ +101.8% |
| 2014 | 1.33x | CN¥328.61 Million | CN¥437.06 Million | ▲ +39.9% |
| 2013 | 0.95x | CN¥490.29 Million | CN¥466.24 Million | ▼ -48.2% |
| 2012 | 1.84x | CN¥243.83 Million | CN¥447.81 Million | ▲ +4.8% |
| 2011 | 1.75x | CN¥197.51 Million | CN¥346.06 Million | ▲ +92.6% |
| 2010 | 0.91x | CN¥299.47 Million | CN¥272.44 Million | ▲ +120.8% |
| 2009 | 0.41x | CN¥317.44 Million | CN¥130.81 Million | ▼ -75.0% |
| 2008 | 1.65x | CN¥84.20 Million | CN¥138.89 Million | ▲ +86.8% |
| 2007 | 0.88x | CN¥136.52 Million | CN¥120.54 Million | ▼ -50.5% |
| 2006 | 1.78x | CN¥77.54 Million | CN¥138.27 Million | ▼ -61.9% |
| 2005 | 4.67x | CN¥53.30 Million | CN¥249.14 Million | ▲ +540.6% |
| 2004 | 0.73x | CN¥163.73 Million | CN¥119.47 Million | ▼ -26.6% |
| 2003 | 0.99x | CN¥47.41 Million | CN¥47.13 Million | ▲ +54.1% |
| 2002 | 0.65x | CN¥75.34 Million | CN¥48.60 Million | ▼ -33.1% |
| 2001 | 0.96x | CN¥37.51 Million | CN¥36.14 Million | — |